Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape

from National Library of Medicine

Timely detection of the pathophysiological changes and cognitive impairment caused by Alzheimer’s disease (AD) is increasingly pressing because of the advent of biomarker-guided targeted therapies that may be most effective when provided early in the disease.